You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
昆藥集團(600422.SH)擬出資2000萬元與華立集團等共同投資柏晟基金
格隆匯 12-29 17:30

格隆匯 12 月 29日丨昆藥集團(600422.SH)公佈,公司擬與華立集團股份有限公司(“華立集團”)及其他機構或自然人投資者等共同投資柏晟基金。該輪投資中,公司擬出資人民幣2000萬元,認繳基金份額,投資完成後,公司將持有柏晟基金10%的基金份額。

此次交易中,公司擬與柏晟基金簽訂《合夥協議》。投資策略:投資於具備一定技術、人才、專利優勢的,預計可以於近兩年內提交上市申報材料的,成熟期擬上市企業,有限合夥一般投資於該等企業上市申報前的最後一輪融資。即投資方向為以Pre-IPO項目為主,重點關注創新藥物研發及高端製造業。

公司經過多年深耕和發展,已在心腦血管、骨科、免疫、抗腫瘤等治療領域形成一定的研發優勢和產品梯度。未來,公司將繼續通過自主研發、投資併購、外部引進等多種形式,重點佈局心腦血管、骨科、自身免疫、抗腫瘤等核心治療領域。公司在保障主營業務經營穩健、資金投向風險相對可控的前提下,運用自有資金參與此次基金認購,通過所投基金的在投項目,能更有效發掘與公司戰略發展相匹配的優質項目,迅速完善和提升公司的創新研發平台,持續豐富創新產品管線,推動公司實現戰略轉型。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account